Table 1.
Pt. | Age (yrs) | GS | Initial Rx | Years from Dx to Ra-223 Rx | Range of Ra-223 administered activity (μCi) | No. of Ra-223 doses received |
---|---|---|---|---|---|---|
1 | 66 | 9 | RP+RT+AD | 18 | 168–175 | 3 |
2 | 58 | n/a | RP | 10 | 119–122 | 2 |
3 | 65 | 9 | RT+RT+AD | 10 | 112 | 2 |
4 | 82 | n/a | RP+RT+AD | 23 | 82–84 | 4 |
5 | 67 | n/a | n/a | n/a | 108–116 | 4 |
6 | 72 | 8 | RP+AD | 20 | 103–106 | 6 |
7 | 66 | n/a | n/a | n/a | 122–133 | 4 |
8 | 76 | 7 | AD | 7 | 92 | 5 |
9 | 71 | 9 | RP | 9 | 100–106 | 4 |
10 | 68 | n/a | RT+RT | 14 | 132–136 | 6 |
11 | 78 | 7 | RT+AD | n/a | 87–91 | 5 |
12 | 67 | 10 | AD | 2 | 77 | 1 |
13 | 81 | 6 | RT+AD | 15 | 100 | 1 |
14 | 64 | 9 | RT+AD | 7 | 96–98 | 6 |
15 | 64 | n/a | AD | 9 | 117 | 2 |
16 | 57 | 6 | RT | 5 | 108–113 | 4 |
17 | 56 | n/a | RP+RT+AD | 5 | 106–113 | 6 |
18 | 81 | n/a | n/a | 6 | 97–100 | 6 |
19 | 75 | n/a | AD | 11 | 82–86 | 6 |
20 | 86 | 6 | AD | 9 | 113 | 1 |
21 | 88 | 8 | RP | 15 | 93–105 | 3 |
22 | 85 | 7 | RP | 11 | 124–125 | 4 |
23 | 65 | n/a | n/a | n/a | 140–145 | 2 |
24 | 70 | 9 | AD | 5 | 128–130 | 2 |
25 | 72 | n/a | n/a | n/a | 103–107 | 2 |
GS, primary tumor Gleason sum score; RP, radical prostatectomy; RT, radiation therapy; AD, androgen deprivation therapy; Dx, diagnosis; Rx, therapy; n/a, not available.